Targeting the causative fusion protein in Ewing's sarcoma
Initially, we focus on Ewing's sarcoma, a paediatric orphan disease. This highly malignant bone tumor occurs with a peak incidence from ages 12 to 18 and is characterized by a strong metastatic potential. Together with one of the largest European Ewing's sarcoma centers and an international team, we develop a new therapeutic concept. The drug candidate is a highly modified siRNA targeting the causative malignant fusion protein EWS-FLI1.